Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity

BACKGROUND: Nanomedicine has emerged as a promising strategy for cancer treatment. The most representative nanomedicine used in clinic is PEGylated liposomal doxorubicin DOXIL(®), which is first FDA-approved nanomedicine. However, several shortcomings, such as low drug loading capacity, low tumor ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Shim, Man Kyu, Yang, Suah, Park, Jooho, Yoon, Jun Sik, Kim, Jinseong, Moon, Yujeong, Shim, Nayeon, Jo, Mihee, Choi, Yongwhan, Kim, Kwangmeyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531438/
https://www.ncbi.nlm.nih.gov/pubmed/36195911
http://dx.doi.org/10.1186/s12951-022-01644-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531438/
https://www.ncbi.nlm.nih.gov/pubmed/36195911
http://dx.doi.org/10.1186/s12951-022-01644-x

Ejemplares similares